ReviewFood science and biotechnology2026
Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.
Review in Food science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Probiotic supplementation reduces IL-6 and improves clinical outcomes in patients with mild-to-moderate COPD: a randomized placebo-controlled trial.BMC pulmonary medicine · 2026Trial
- Emerging Microbiome-Based Therapies for Skin Infections: From Probiotics and Prebiotics to Synthetic Microbiome Engineering.Infection and drug resistance · 2026Review
- From gut-reproductive microbiota to ferroptosis: a comprehensive insight into the molecular-pathogenicity of endometriosis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postbiotics, the metabolic byproducts of probiotic bacteria, have emerged as promising therapeutic agents for managing inflammation-mediated metabolic disorders. Postbiotics offer greater stability and standardization compared to probiotics, as they do not rely on live bacteria for their effects. These bioactive compounds including organic acids, peptides, short-chain fatty acids, enzymes, and exopolysaccharides play a crucial role in modulating immune responses, enhancing intestinal barrier function, and reducing chronic inflammation. Inflammation is a key factor in the development of metabolic disorders such as obesity, type 2 diabetes, metabolic syndrome, NAFLD, and cardiovascular diseases. By targeting multiple molecular pathways such as TLR4/NF-κB signaling, NLRP3 inflammasome activation, Treg/Th17 cell balance, AMPK pathway, MLCK inhibition, NLRC3-TRAF6 axis, AhR signaling, and STAT3-mediated mucin synthesis, postbiotics exert anti-inflammatory and gut-protective effects. These mechanisms include inhibition of pro-inflammatory cytokines, reduction of oxidative stress, improvement of tight junction integrity, and modulation of gut microbiota composition. Additionally, postbiotics have been shown to positively influence gut-brain signalling, contributing to better metabolic health and weight management. This review delves into the molecular mechanisms by which postbiotics regulate inflammatory pathways and metabolic processes. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.